Results 31 to 40 of about 8,174 (197)

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

open access: yes, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo   +16 more
core   +1 more source

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

open access: yesKidney International Reports, 2017
There is paucity of data on sofosubvir (SOF)−based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India.
Sanjay Kumar Agarwal   +2 more
doaj   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

open access: yes, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G   +12 more
core   +3 more sources

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

open access: yesOne Health & Risk Management, 2020
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU   +2 more
doaj   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

open access: yes, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia   +2 more
core   +1 more source

Visualization of positive and negative sense viral RNA for probing the mechanism of direct-acting antivirals against hepatitis C virus [PDF]

open access: yes, 2019
RNA viruses are highly successful pathogens and are the causative agents for many important diseases. To fully understand the replication of these viruses it is necessary to address the roles of both positive-strand RNA ((+)RNA) and negative-strand RNA ((
Bassit, Leda C   +13 more
core   +2 more sources

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

open access: yes, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward   +5 more
core   +2 more sources

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture

open access: yesFrontiers in Microbiology, 2022
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection.
Carlos García-Crespo   +21 more
doaj   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

open access: yes, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS   +6 more
core   +2 more sources

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy

open access: yesArchives of Pharmaceutical Sciences Ain Shams University, 2021
Hepatitis C virus (HCV) was first identified in 1989. The situation in Egypt is really dire. The prevalence of HCV genotype 4 (GT-4) is 14.7%. About 10% of the middle-aged population (ages 15 to 59) is infected with HCV.
Heba Elbadawy   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy